Key result
Homozygous UCP2 mutated haplotype is linked to ~114% greater DKD risk in T2D.
Why the study?
Deleterious polymorphisms in the UCP2 gene are candidate risk factors for diabetic kidney disease in type 2 diabetes mellitus patients due to their role in reducing mitochondrial ROS production.
Is the UCP2 -866A/55Val/Ins haplotype associated with diabetic kidney disease and altered UCP2 gene expression in patients with type 2 diabetes mellitus?
Case-Control (n=568)
Yes
Is the UCP2 -866A/55Val/Ins haplotype associated with diabetic kidney disease and altered UCP2 gene expression in patients with type 2 diabetes mellitus?
Odds Ratio: 2.136 (95% CI 1.036–4.404)
Absolute Event Rate: 11.1% vs 6.5%
p-value: p=0.040
The UCP2 -866A/55Val/Ins haplotype is associated with an increased risk of diabetic kidney disease, lower eGFR, and decreased UCP2 gene expression in human kidneys.
May flag higher DKD risk in T2DM for closer surveillance; leaves open causal UCP2 role and need for prospective validation.
INTRODUCTION: Uncoupling protein 2 (UCP2) reduces production of reactive oxygen species (ROS) by mitochondria. ROS overproduction is one of the major contributors to the pathogenesis of chronic diabetic complications, such as diabetic kidney disease (DKD). Thus, deleterious polymorphisms in the UCP2 gene are candidate risk factors for DKD. In this study, we investigated whether UCP2 -866G/A, Ala55Val and Ins/Del polymorphisms were associated with DKD in patients with type 2 diabetes mellitus (T2DM), and whether they had an effect on UCP2 gene expression in human kidney tissue biopsies. MATERIALS AND METHODS: In a case-control study, frequencies of the UCP2 -866G/A, Ala55Val and Ins/Del polymorphisms as well as frequencies of the haplotypes constituted by them were analyzed in 287 T2DM patients with DKD and 281 T2DM patients without this complication. In a cross-sectional study, UCP2 gene expression was evaluated in 42 kidney biopsy samples stratified according to the presence of the UCP2 mutated -866A/55Val/Ins haplotype. RESULTS: In the T2DM group, multivariate logistic regression analysis showed that the -866A/55Val/Ins haplotype was an independent risk factor for DKD (OR = 2.136, 95% CI 1.036-4.404), although neither genotype nor allele frequencies of the individual polymorphisms differed between case and control groups. Interestingly, T2DM patients carrying the mutated haplotype showed decreased estimated glomerular filtration rate (eGFR) when compared to subjects with the reference haplotype (adjusted P= 0.035). In kidney biopsy samples, UCP2 expression was significantly decreased in UCP2 mutated haplotype carriers when compared to kidneys from patients with the reference haplotype (0.32 ± 1.20 vs. 1.85 ± 1.16 n fold change; adjusted P< 0.000001). DISCUSSION: Data reported here suggest that the UCP2 -866A/55Val/Ins haplotype is associated with an increased risk for DKD and with a lower eGFR in T2DM patients. Furthermore, this mutated haplotype was associated with decreased UCP2 gene expression in human kidneys.
No takes yet. Share an insight, caveat, or question.
Souza et al. (2015) conducted a case-control in Diabetic Kidney Disease in Type 2 Diabetes Mellitus (n=568). UCP2 -866A/55Val/Ins mutated haplotype vs. Reference or other haplotypes was evaluated on Diabetic kidney disease (DKD) (OR 2.136, 95% CI 1.036-4.404, p=0.040). Homozygosity for the UCP2 -866A/55Val/Ins mutated haplotype was independently associated with an increased risk of diabetic kidney disease in patients with type 2 diabetes (OR 2.136).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: